スギタニ　ナオヒロ   Sugitani Naohiro   杉谷　直大    所属   その他 その他    職種   嘱託医師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids.
掲載誌名	正式名：Modern rheumatology 略　 称：Mod Rheumatol ISSNコード：14397609/14397595
巻・号・頁	32(3),pp.522-527
著者・共著者	Yamaguchi Rei, Tanaka Eiichi, Nakajima Ayako, Inoue Eisuke, Abe Mai, Sugano Eri, Sugitani Naohiro, Saka Kumiko, Ochiai Moeko, Higuchi Yoko, Sugimoto Naoki, Ikari Katsunori, Yamanaka Hisashi, Harigai Masayoshi
発行年月	2022/04/18
概要	OBJECTIVES:To elucidate the incidence and risk factors of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) in the biologics era.METHODS:We determined the rate of HZ occurrence among the RA patients that participated in the Institute of Rheumatology, Rheumatoid Arthritis surveys from 2011 to 2015, by assessing medical records. The standardised incidence rate per 1000 patient-years with a 95% confidence interval (CI) was calculated, and risk factors for HZ were analysed using a time-dependent Cox regression analysis.RESULTS:Among 7815 patients (female, 84.7%) contributing to 25,863 patient-years of observation, 340 HZ events in 309 patients were confirmed. The standardised incidence rate (95% CI) per 1000 patient-years was 8.5 (6.9-10.5) in total, 6.0 (3.7-9.2) in men, and 11.0 (8.7-13.7) in women. Risk factors for HZ were age per 10 years (hazard ratio 1.14, 95% CI 1.03-1.26, p < .05), Japanese version of the Health Assessment Questionnaire (J-HAQ) score of 0.5-1.5 (versus J-HAQ = 0; 1.51, 1.09-2.10, p < .05), methotrexate use (1.58, 1.06-2.36, p < .05), and biologic use (1.88, 1.44-2.47, p < .01).CONCLUSIONS:In the era when biologics were frequently used and corticosteroid use and doses were decreasing, methotrexate and biologics increased the risk for HZ.
DOI	10.1093/mr/roab026
PMID	34897494